---
title: "BUZZ-Street View: Device blues can't dim J&J's pipeline glow"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292869702.md"
datetime: "2026-07-16T07:32:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292869702.md)
  - [en](https://longbridge.com/en/news/292869702.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292869702.md)
---

# BUZZ-Street View: Device blues can't dim J&J's pipeline glow

Johnson & Johnson (JNJ.N) said on Wednesday that its medical device unit underperformed in the second quarter, even as strong sales of Tremfya for autoimmune conditions and cancer treatment Darzalex helped it beat Wall Street estimates

Twenty-seven analysts rate the stock “Buy” on average; median PT $270 - data compiled by LSEG NEW KIDS ON THE BLOCK

J.P. Morgan (“Neutral”) expects J&J’s immunology business to remain strong, with Icotyde contributing more growth by 2027, but weaker demand for Impella heart pumps may weigh on second-half results, putting the focus on heart-device unit’s recovery

Morgan Stanley (“Overweight,” PT: $294) says J&J continues to evaluate all options for separating its orthopedics business, which remains on track for completion in mid-2027

Leerink Partners (“Outperform,” PT: $276) says that Icotyde, its treatment for plaque psoriasis, is outperforming most recent launches, and expects to see key late-stage trial data that could support approval in a form of kidney cancer

RBC Capital Markets (“Outperform,” PT: $287) says J&J’s new drug launches support faster growth from 2027 and strengthen its goal of becoming the top oncology company by 2030, while delivering double-digit growth by decade-end

### Related Stocks

- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)
- [JPM.US](https://longbridge.com/en/quote/JPM.US.md)
- [MS.US](https://longbridge.com/en/quote/MS.US.md)
- [LSEG.UK](https://longbridge.com/en/quote/LSEG.UK.md)
- [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md)
- [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md)
- [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md)
- [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md)
- [8634.JP](https://longbridge.com/en/quote/8634.JP.md)
- [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md)
- [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md)
- [MS-O.US](https://longbridge.com/en/quote/MS-O.US.md)
- [MS-Q.US](https://longbridge.com/en/quote/MS-Q.US.md)
- [MS-E.US](https://longbridge.com/en/quote/MS-E.US.md)
- [MS-I.US](https://longbridge.com/en/quote/MS-I.US.md)
- [MS-L.US](https://longbridge.com/en/quote/MS-L.US.md)
- [MS-P.US](https://longbridge.com/en/quote/MS-P.US.md)
- [MS-A.US](https://longbridge.com/en/quote/MS-A.US.md)
- [MS-F.US](https://longbridge.com/en/quote/MS-F.US.md)
- [MS-K.US](https://longbridge.com/en/quote/MS-K.US.md)

## Related News & Research

- [Dorsey Wright & Associates Buys 8,953 Shares of Johnson & Johnson $JNJ](https://longbridge.com/en/news/293179677.md)
- [Johnson & Johnson wins FDA De Novo clearance for OTTAVA robotic surgery system in US](https://longbridge.com/en/news/293462534.md)
- [J&J, Time to name Healthcare Champion of the Year](https://longbridge.com/en/news/293242387.md)
- [J&J names C1DO1, Curium Life Tech, iQ Surgical as Polyphonic AI Fund for Surgery cohort at SRS meeting](https://longbridge.com/en/news/293630635.md)
- [J&J falls premarket despite Q2 beats, updated guidance](https://longbridge.com/en/news/292758364.md)